Vaxxilon is advancing multiple programs quickly.
We are actively seeking research collaborations or strategic partnerships to accelerate our programs and create new vaccines.
Based on knowledge of natural capsular polysaccharides, Vaxxilon scientists can synthesize a library of novel carbohydrate antigens based on length and terminal sugar. They can then select the optimal epitope with in vitro techniques prior to in vivo confirmation studies.
Please contact us if you are interested in global/regional partnerships for projects in the portfolio or would like to collaborate with Vaxxilon on new vaccine targets.
Christoph Merian-Ring 11,
4153 Reinach, Switzerland
Vaxxilon Deutschland GmbH
12489 Berlin, Germany